UNSPSC 51182025: Enestebol

This classification denotes an anabolic steroid with the molecular formula C20H28O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LNS3MVH7NV, chemically known as 4,17beta-dihydroxy-17-methyl-androsta-1,4-dien-3-one, but generally known as enestebol, which bears US NIH Compound Identifier 208919. European Medicines Agency schedules Enestebol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06528MIG.

UNSPSC 51182025 Enestebol, a Commodity code, encompasses generic multi-source pharmaceuticals and over-the-counter products distributed through state and local government cooperative purchasing networks. State and local governments procure these items primarily through multistate cooperative purchasing alliances and state health or pharmaceutical benefit programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a principal issuing body for this category, managing contracts that span multiple states including Oregon and serving state and local facilities across participating jurisdictions.

MMCAP posted a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates cGMP certification, Drug Supply Chain Security Act compliance, and contractual relationships with at least two of the three wholesalers. Pricing evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new responders with optional extensions, while incumbent amendments extend through June 30, 2028. Products must be available in the marketplace by May 15, 2026, with awarded contracts effective July 1, 2026. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and all products must comply with FDA requirements with minimum one-year expiration dates from manufacture and six-month shelf life guarantees.